- Home
- ACET vs ALIS Comparison
ACET vs ALIS Comparison
Compare ACET & ALIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACET | ALIS |
|---|---|---|
| Founded | 1947 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 85.9M |
| IPO Year | 2017 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ACET | ALIS |
|---|---|---|
| Price | $9.59 | $10.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $48.33 | N/A |
| AVG Volume (30 Days) | ★ 80.5K | 48.7K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $256.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $9.87 |
| 52 Week High | $9.84 | $10.26 |
Technical Indicators
Market Signals| Indicator | ACET | ALIS |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 72.49 |
| Support Level | $7.45 | $10.05 |
| Resistance Level | $9.59 | N/A |
| Average True Range (ATR) | 0.53 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 73.95 | 87.50 |
Price Performance
Historical ComparisonAbout ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
About ALIS Calisa Acquisition Corp Ordinary shares
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.